"HT-29人結(jié)腸癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長(zhǎng)特性：貼壁生長(zhǎng)

公司細(xì)胞系形態(tài)漂亮、增殖倍數(shù)高、純度高、功能性強(qiáng)，細(xì)胞培養(yǎng)就跟養(yǎng)孩子一個(gè)樣。養(yǎng)孩子要喂奶，養(yǎng)細(xì)胞要加補(bǔ)液，都需要在前期補(bǔ)充足夠的營(yíng)養(yǎng)，初始狀態(tài)的細(xì)胞或剛剛復(fù)蘇的細(xì)胞還要適量加入血清或細(xì)胞因子來幫助它們的存活增殖，如果營(yíng)養(yǎng)物質(zhì)缺乏，細(xì)胞就會(huì)不生長(zhǎng)甚至死亡。養(yǎng)孩子要從小培養(yǎng)學(xué)習(xí)，養(yǎng)細(xì)胞也得培養(yǎng)寶寶順利生下來，你會(huì)經(jīng)常撫摸他，給他看各種顏色，刺激他的五感。細(xì)胞也是一樣，分離后的細(xì)胞需要使用特定的細(xì)胞因子進(jìn)行活化、增殖。另外加入因子的種類、因子的濃度、加入時(shí)間、加入順序都會(huì)影響細(xì)胞最終的結(jié)果。養(yǎng)孩子最怕孩子生病，養(yǎng)細(xì)胞最怕被污染，平時(shí)你會(huì)仔細(xì)觀察寶寶是否嘔吐、是否突然哭鬧，猜測(cè)寶寶是否生病了。對(duì)于細(xì)胞，我們也需要時(shí)刻進(jìn)行觀察的，假如培養(yǎng)液渾濁(污染了)，則需要換液后加抗生素；假如細(xì)胞增殖不明顯，形態(tài)變差，則可能是因?yàn)闋I(yíng)養(yǎng)不足了，對(duì)貼壁細(xì)胞可以消化后重新用新的培養(yǎng)基接種并加倍加入細(xì)胞因子含量；對(duì)懸浮細(xì)胞增殖能力不強(qiáng)的，則不著急補(bǔ)液，只是先補(bǔ)加血清、細(xì)胞因子看是否可以好轉(zhuǎn)。培養(yǎng)時(shí)還得全程在無(wú)菌的環(huán)境，一個(gè)小小的偏差，細(xì)胞就會(huì)死亡。

換液周期：每周2-3次

Potorous tridactylus Kidney 2 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：KYSE30細(xì)胞、RCC 7860細(xì)胞、Farage細(xì)胞

OE33 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HPMC細(xì)胞、Ramos 2G6 4C10細(xì)胞、SK Hep1細(xì)胞

CWR22Rv1 Cells;背景說明：２２RV１是來自異種移植(在閹割引起前列腺癌衰退又在其父親的雄性激素信賴型CWR２２嫁接后復(fù)發(fā)的小鼠中連續(xù)傳代)的人前列腺癌上皮細(xì)胞系。此細(xì)胞系表達(dá)前列腺特異抗原。二羥基睪丸脂酮輕微刺激細(xì)胞生長(zhǎng)，經(jīng)westernblot檢測(cè)溶解產(chǎn)物與抗雄性激素受體抗體起免疫反應(yīng)。EGF刺激細(xì)胞生長(zhǎng)，但TGFβ-１不能抑制細(xì)胞生長(zhǎng)。該細(xì)胞在裸鼠中成瘤。;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：NCI-H2110細(xì)胞、Det 562細(xì)胞、HME-1細(xì)胞

HT-29人結(jié)腸癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

背景信息：該細(xì)胞是１９６４年由FoghJ用移植培養(yǎng)方法和含１５%FBS的F１２培養(yǎng)從原發(fā)性腫瘤分離的。近來，已建株的培養(yǎng)細(xì)胞用含血清的McCoy＇s５a培養(yǎng)基培養(yǎng)。該細(xì)胞系在裸鼠中成瘤，也能在類固醇處理的地鼠中成瘤。該細(xì)胞可合成IgA、A、TGFβ結(jié)合蛋白和黏素；表達(dá)尿激酶受體，但沒有檢測(cè)到血漿酶原活性；不表達(dá)CD４，但細(xì)胞表面表達(dá)半乳糖神經(jīng)酰胺（HIV的可能替代受體）。該細(xì)胞系癌基因c-myc、K-ras、H-ras、N-ras、Myb、sis、fos陽(yáng)性；p５３基因過表達(dá)，并且在２７３位密碼子處發(fā)

┈訂┈購(gòu)(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號(hào)】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

DSMZ菌株保藏中心成立于1969年，是德國(guó)的國(guó)家菌種保藏中心。該中心一直致力于細(xì)菌、真菌、質(zhì)粒、抗菌素、人體和動(dòng)物細(xì)胞、植物病毒等的分類、鑒定和保藏工作。DSMZ菌種保藏中心是歐洲規(guī)模最大的生物資源中心，保藏有動(dòng)物細(xì)胞500多株。Riken BRC成立于1920年，是英國(guó)的國(guó)家菌種保藏中心。該中心一直致力于細(xì)菌、真菌、植物病毒等的分類、鑒定和保藏工作。日本Riken BRC(Riken生物資源保藏中心)是全球三大典型培養(yǎng)物收集中心之一。Riken保藏中心提供了很多細(xì)胞系。在世界范圍內(nèi)，這些細(xì)胞系，都在醫(yī)學(xué)、科學(xué)和獸醫(yī)中具有重要意義。Riken生物資源中心支持了各種學(xué)術(shù)、健康、食品和獸醫(yī)機(jī)構(gòu)的研究工作，并在世界各地不同組織的微生物實(shí)驗(yàn)室和研究機(jī)構(gòu)中使用。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來源說明：細(xì)胞主要來源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫(kù)

HT-29人結(jié)腸癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

物種來源：人源、鼠源等其它物種來源

NCC-IT Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４—１：８?jìng)鞔?，每周換液２—３次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：NCI-H2198細(xì)胞、MGHU1細(xì)胞、SUP-T1細(xì)胞

V 79 Cells;背景說明：肺；自發(fā)永生；雄性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Liver-02細(xì)胞、LS 123細(xì)胞、Microbiological Associates-104細(xì)胞

NCIH1651 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：８?jìng)鞔?，每周換液２次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：KG-1細(xì)胞、HuT 78細(xì)胞、NCIH1792細(xì)胞

HNE-1 Cells;背景說明：鼻咽部；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SP-2細(xì)胞、DMS 79細(xì)胞、NCI-SNU-119細(xì)胞

┈訂┈購(gòu)(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號(hào)】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

形態(tài)特性：上皮細(xì)胞樣

細(xì)胞復(fù)蘇后貼壁細(xì)胞較少的問題分析：總結(jié)１：復(fù)蘇過程沒有問題，是否是從拿出直接放入溫水，還有培養(yǎng)箱，二氧化碳濃度，培養(yǎng)基、PH值等環(huán)節(jié)。要么加GAO濃度FBS １５-２０%，看看能否幫助貼壁，當(dāng)然也需要考慮血清問題，還有確信拿來的細(xì)胞沒問題。總結(jié)２：首先應(yīng)該懷疑凍存，實(shí)際上復(fù)蘇出問題的可能非常小，因?yàn)椴僮骱?jiǎn)單，而且死板。１、你凍存的時(shí)候是不是消化的時(shí)間過長(zhǎng)，這是一般人所注意不到的，即使書上也不講這個(gè)問題，太長(zhǎng)的消化時(shí)間會(huì)讓細(xì)胞復(fù)蘇時(shí)失去貼壁能力，表現(xiàn)為先貼后死，原因是在你復(fù)蘇的時(shí)候細(xì)胞已進(jìn)入凋亡程序，不可逆轉(zhuǎn)的死亡。２、你的凍存HAO不HAO，是什么，甘油還是DMSO，質(zhì)量非常重要，否則也會(huì)死亡。３、你的凍存的量加的是不是太多，AC推薦是不超過７%，大于５%，太多也不HAO。４、你在凍存的時(shí)候是不是把DMSO混均勻，這個(gè)有一些影響，但不算太大。５、你的凍存是否按部就班，就是所溫度梯度是不是把握嚴(yán)格，很多人容易忘卻這個(gè)事情，因?yàn)檫@個(gè)東西流程長(zhǎng)。６、如果你細(xì)胞污染，你是否能很快看到，我比我的導(dǎo)師能早一天看到污染。從這個(gè)角度講建議去除離心這步。７、你的細(xì)胞在凍存前是否過密。還有，不贊成孵箱污染這個(gè)概念的，所有在一個(gè)孵箱里的細(xì)胞都污染一個(gè)細(xì)菌的話，這個(gè)細(xì)菌是源于孵箱的，但這不代表孵箱污染，因?yàn)榉跸錈o(wú)論你如何處理都有大量的細(xì)菌，問題在操作。每次污染的原因都要盡可能的找，以后就不犯同樣的問題，這個(gè)很重要，不能靠猜，否則你就有可能細(xì)胞養(yǎng)絕Zui后換課題，這個(gè)見得太多了，別不當(dāng)會(huì)事。

EFM-192A Cells;背景說明：乳腺癌；胸腔積液轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H524細(xì)胞、Anip 973細(xì)胞、Mv1Lu細(xì)胞

SUM52 Cells;背景說明：乳腺癌；胸腔積液轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PC-12細(xì)胞、NCIH2081細(xì)胞、NCI-H524細(xì)胞

SUDHL4 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：3T3-Swiss albino細(xì)胞、MPC-11細(xì)胞、GM0637細(xì)胞

NTERA-2 Cells;背景說明：畸胎瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：TCMK1細(xì)胞、FD-LSC-1細(xì)胞、NCI-H378細(xì)胞

SK-N-F1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４傳代，每周換液２次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Hs 274.T細(xì)胞、IM-95細(xì)胞、SW 1271細(xì)胞

H-220 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Cor L51細(xì)胞、SV-HUC-1細(xì)胞、PK 15細(xì)胞

RM1 Cells;背景說明：前列腺癌；C５７BL/６;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCIH208細(xì)胞、RAMSCs細(xì)胞、CFPAC-1細(xì)胞

OVCAR-420 Cells;背景說明：卵巢癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：LICR-HN-6細(xì)胞、MDA435細(xì)胞、SNU-216細(xì)胞

LLC-PK1 Cells;背景說明：腎；自發(fā)永生；Hampshire;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：TR146細(xì)胞、RBE4細(xì)胞、A549/ATCC細(xì)胞

HCT 8 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：KNS42細(xì)胞、P-388D1細(xì)胞、WEHI 231細(xì)胞

Hu-P-T4 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：COV362細(xì)胞、697細(xì)胞、Menschliche Und Tierische Zellkulture-3細(xì)胞

TK-10 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代；２-３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Panc 03.27細(xì)胞、FLC-7細(xì)胞、Hep2細(xì)胞

NCIH2172 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MCA-205細(xì)胞、KY-50細(xì)胞、HBMEC細(xì)胞

C3H10T1/2CL8 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SKNFI細(xì)胞、TE-15細(xì)胞、H-2073細(xì)胞

MDA-MB436 Cells;背景說明：該細(xì)胞源于一名４３歲患有乳腺腺癌女性的胸腔積液。;傳代方法：１：２傳代，每周換液２—３次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：多角形;相關(guān)產(chǎn)品有：LA-795細(xì)胞、X63Ag8.653細(xì)胞、Colon 38細(xì)胞

VP 229 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：COLO-680N細(xì)胞、BTI-Tn-5B1-4細(xì)胞、UM-UC3細(xì)胞

SK 1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：維持細(xì)胞濃度在１×１０５-２×１０５,每周補(bǔ)液２-３次。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：球形的;相關(guān)產(chǎn)品有：Colo-206F細(xì)胞、SW 756細(xì)胞、Hep 3B2細(xì)胞

Abcam HEK293T EIF2AK4 KO 1 Cells(提供STR鑒定圖譜)

AG09980 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line NPX373 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XC597 Cells(提供STR鑒定圖譜)

BT-L Cells(提供STR鑒定圖譜)

COST Cells(提供STR鑒定圖譜)

DA04061 Cells(提供STR鑒定圖譜)

DA05931 Cells(提供STR鑒定圖譜)

GM00298 Cells(提供STR鑒定圖譜)

JVM-2 Cells;背景說明：該細(xì)胞是 J.V.Melo從一位６３歲患有套細(xì)胞淋巴瘤白人女性外周血中分離建立的，經(jīng)EBV介導(dǎo)獲得永生化，該細(xì)胞表達(dá)p１６和細(xì)胞周期蛋白D２,低水平表達(dá)細(xì)胞周期蛋白D１。;傳代方法：１：３傳代,２-３天傳一代;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：3T3-L1 ad細(xì)胞、Caco-2 BBe細(xì)胞、SaOS-2細(xì)胞

HT-29人結(jié)腸癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

MRC-5 Cells;背景說明：MRC-５細(xì)胞系來自１４周齡男性胎兒的正常肺組織，該細(xì)胞老化前能傳代４２~４６個(gè)倍增時(shí)間。;傳代方法：１：２-１：５傳代；每周１-２次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：Huh7.5細(xì)胞、SW 780細(xì)胞、ST2細(xì)胞

FF-WT-BJ Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：hTERT-HPNE細(xì)胞、R 2 C細(xì)胞、H-4細(xì)胞

SW-1463 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：８?jìng)鞔?，每周換液１-２次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：HO1-N-1細(xì)胞、MCF.7細(xì)胞、BEAS2B細(xì)胞

Walker256-TC Cells;背景說明：乳腺癌；雌性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：WM239細(xì)胞、SW-954細(xì)胞、HN4細(xì)胞

IMR 32 Cells;背景說明：該細(xì)胞是１９６７年４月由NicholsWW,LeeJ和DwightS建立，來源于一名１３月齡白人男嬰腹部腫塊，臨床診斷為神經(jīng)母細(xì)胞瘤，伴有極少部位的類器官樣分化。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：存在兩種細(xì)胞類型，小的神經(jīng)母細(xì)胞樣細(xì)胞和大的透明成纖維樣細(xì)胞;相關(guān)產(chǎn)品有：RenCa細(xì)胞、MDA-MB-134 VI細(xì)胞、H1048細(xì)胞

28F11 Cells(提供STR鑒定圖譜)

Ca 9-22 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：Caco-2 BBe細(xì)胞、CHL細(xì)胞、CHP212細(xì)胞

H-322 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：LOU-NH91細(xì)胞、NCI-H125細(xì)胞、KLM1細(xì)胞

NCIH2030 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：４傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：DoHH-2細(xì)胞、RH-30細(xì)胞、GP2-293細(xì)胞

MT-4 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞樣；圓形;相關(guān)產(chǎn)品有：HPAC細(xì)胞、PANC0813細(xì)胞、BBE細(xì)胞

JOSK-M Cells;背景說明：急性單核細(xì)胞白血??；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SKNO-1細(xì)胞、Colo699細(xì)胞、HcaF細(xì)胞

CRFK Cells;背景說明：腎；自發(fā)永生；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：TCC-PAN2細(xì)胞、JVM3細(xì)胞、NCI.H522細(xì)胞

HPAF-II Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Reh細(xì)胞、DMS114細(xì)胞、A375-SM細(xì)胞

Asian Medical Center-Head and Neck cancer-8 Cells;背景說明：喉癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：L 540細(xì)胞、RMC細(xì)胞、P3-X63-Ag8-653細(xì)胞

GM28012 Cells(提供STR鑒定圖譜)

HAP1 PARP6 (-) 3 Cells(提供STR鑒定圖譜)

Mo7e Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H-2196細(xì)胞、CAKI 2細(xì)胞、NCI-H510細(xì)胞

NCIH2009 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：FD-LSC-1細(xì)胞、CCD1095Sk細(xì)胞、CT26.WT細(xì)胞

RAMOS2G64C10 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法： 維持細(xì)胞濃度在２×１０５/ml-１×１０６/ml；根據(jù)細(xì)胞濃度每２-３天補(bǔ)液１次。;生長(zhǎng)特性：懸浮生長(zhǎng) ;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：McCoy細(xì)胞、MADB106細(xì)胞、U-87MG細(xì)胞

Rat-1 Cells;背景說明：成纖維細(xì)胞；自發(fā)永生；Fischer ３４４;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：GM00215A細(xì)胞、MDA231細(xì)胞、KU-812-F細(xì)胞

Ketr3 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng)　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HRA19細(xì)胞、VE細(xì)胞、RPMI7666細(xì)胞

H647ell Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代；每周換液２次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SMMC-7721細(xì)胞、C3H10T1/2細(xì)胞、OCIAML4細(xì)胞

624 Cells;背景說明：黑色素瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MCMEC細(xì)胞、D10.G4.1細(xì)胞、CMT 64細(xì)胞

HCC-1588 Cells;背景說明：肺鱗癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：H-2087細(xì)胞、ARH77細(xì)胞、KU 19-19細(xì)胞

HS-24 Cells(提供STR鑒定圖譜)

KOLF2.1J GBA1 D448V SNV/SNV Cells(提供STR鑒定圖譜)

MMPR-11 Cells(提供STR鑒定圖譜)

NUIGi033-A Cells(提供STR鑒定圖譜)

RG-201 Cells(提供STR鑒定圖譜)

Ubigene HCT 116 YAP1 KO Cells(提供STR鑒定圖譜)

WBD001816 Cells(提供STR鑒定圖譜)

HG02056 Cells(提供STR鑒定圖譜)

MCF 7B Cells;背景說明：浸潤(rùn)性導(dǎo)管癌；胸腔積液轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：J-111細(xì)胞、CCD 1112SK細(xì)胞、Hep 2細(xì)胞

Leukemia L1210 Cells;背景說明：該細(xì)胞源于用０.２%甲基膽蒽（溶解）涂抹雌性小鼠的皮膚誘發(fā)的腫瘤，鼠痘病毒陰性。;傳代方法：１：２傳代;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：Normal Rat, August 3, 1983細(xì)胞、NCI.H226細(xì)胞、HCGC細(xì)胞

A2780/Taxol Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：RT112細(xì)胞、OVMANA細(xì)胞、HSC/mHSC細(xì)胞

Pa017C Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：PLA802細(xì)胞、CWR22Rv1細(xì)胞、Li-7細(xì)胞

b.End3 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Calu 6細(xì)胞、C1498細(xì)胞、8305-C細(xì)胞

NWA Cells;背景說明：這株細(xì)胞有EB病毒基因組。;傳代方法：１：２傳代。３天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性：懸浮生長(zhǎng) ;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：NCI H2106細(xì)胞、OCI AML3細(xì)胞、Natural Killer-92細(xì)胞

Swiss 3T3 Cells;背景說明：３T３細(xì)胞株是１９６２年Todaro G和Green H從分離的瑞士小鼠胚胎中建立的；該細(xì)胞的生長(zhǎng)受接觸性抑制，匯合狀態(tài)的單層細(xì)胞密度為４００００個(gè)細(xì)胞/平方厘米；檢測(cè)結(jié)果顯示該細(xì)胞鼠痘病毒陰性；在中生長(zhǎng)較好，在某些玻璃表面上可能狀態(tài)不佳；細(xì)胞生長(zhǎng)飽和時(shí)其密度可以達(dá)到約５００００ cells/cm２。;傳代方法：１：３傳代；３-４天１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：JROECL 19細(xì)胞、624細(xì)胞、HNE2細(xì)胞

SU-DHL6 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：６傳代，３—４天換液１次;生長(zhǎng)特性：懸浮生長(zhǎng) ;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：HuT78細(xì)胞、NCI-H661細(xì)胞、IOSE-29細(xì)胞

SK-N-BE-2 Cells;背景說明：１９７２年１１月從一們多次化療及放療的擴(kuò)散性神經(jīng)母細(xì)胞瘤患兒骨髓穿刺物中建立了SK-N-BE(２)神經(jīng)母細(xì)胞瘤細(xì)胞株。 該細(xì)胞顯示中等水平的多巴胺-β-羥基酶活性。 有報(bào)道稱SK-N-BE(２)細(xì)胞的飽和濃度超過１x１０６細(xì)胞/平方厘米。細(xì)胞形態(tài)多樣，有的有長(zhǎng)突觸，有的呈上皮細(xì)胞樣。 細(xì)胞會(huì)聚集，形成團(tuán)塊并浮起;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：ID8/MOSEC細(xì)胞、BpRc1細(xì)胞、SK-CO-1細(xì)胞

CCRF/CEM Cells;背景說明：G.E. Foley 等人建立了類淋巴母細(xì)胞細(xì)胞株CCRF-CEM。 細(xì)胞是１９６４年１１月從一位四歲白人女性急性淋巴細(xì)胞白血病患者的外周血白血球衣中得到。此細(xì)胞系從香港收集而來。;傳代方法：１：２傳代。３天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：M-1細(xì)胞、PL 5細(xì)胞、DHBE細(xì)胞

OAW-42 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SKNDZ細(xì)胞、Granta519細(xì)胞、NCIH2085細(xì)胞

OCI/AML-2 Cells;背景說明：急性髓系白血?。荒行?傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HCC94細(xì)胞、SKNFI細(xì)胞、HC11細(xì)胞

SF126 Cells;背景說明：該細(xì)胞來源于星形膠質(zhì)細(xì)胞瘤；膠質(zhì)纖維酸性蛋白（GFAP）陰性；可以特異地結(jié)合β-內(nèi)啡肽。;傳代方法：１：３傳代；３-４天１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：KMH-2細(xì)胞、MCA 205細(xì)胞、MKN 7細(xì)胞

B16-F10 Cells;背景說明：B１６-F１０是B１６-F０的亞系。;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Sp2/mIL-6細(xì)胞、HEK293-A細(xì)胞、EU-4細(xì)胞

U-343-MG Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng)　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OUMS-27細(xì)胞、CMT 93細(xì)胞、H1568細(xì)胞

STBCi283-A Cells(提供STR鑒定圖譜)

ECC12 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HEK-EBNA細(xì)胞、U-118 MG細(xì)胞、Tadarida brasiliensis 1 lung細(xì)胞

S91 Cells;背景說明：黑色素瘤；雄性；DBA;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：EFM192細(xì)胞、Walker-256細(xì)胞、MDAMB134細(xì)胞

Hs 863.T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：CHO-Lec1細(xì)胞、A431細(xì)胞、WEHI-231細(xì)胞

PL11 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：BHK細(xì)胞、Madin Darby Canine Kidney細(xì)胞、PF-382細(xì)胞

MIN6 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCIH1568細(xì)胞、10RGB細(xì)胞、LS 123細(xì)胞

AX-Mel Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：６傳代，２-３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：TCMK-1細(xì)胞、OCUM-1細(xì)胞、AE 1201細(xì)胞

HT-29人結(jié)腸癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

SNU-423 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：CNE-2細(xì)胞、SRA01/04 (HLE)細(xì)胞、CTLA4 Ig-24細(xì)胞

U-118-MG Cells;背景說明：注意： 據(jù)報(bào)道來自不同個(gè)體的膠質(zhì)母細(xì)胞瘤細(xì)胞株U-１１８ MG (HTB-１５) 和 U-１３８ MG (HTB-１６)有著一致的VNTR和相近的STR模式。 U-１１８ MG 和 U-１３８ MG細(xì)胞遺傳學(xué)上很相似并有至少六個(gè)衍生標(biāo)記染色體。 這是１９６６年至１９６９年間J. Ponten和同事從惡性神經(jīng)膠質(zhì)瘤中構(gòu)建的細(xì)胞株中的一株(其它包括ATCC HTB-１４和 ATCC HTB-１６ and ATCC HTB-１７)。 １９８７年用BM-Cycline培養(yǎng)６周去除了支原體污染。 ;傳代方法： 消化３-５分鐘。１：２傳代。３天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：混合型;相關(guān)產(chǎn)品有：KP4細(xì)胞、Hs611T細(xì)胞、NB-9細(xì)胞

STTG1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：６傳代；每周換液２-３次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：星形膠質(zhì)細(xì)胞;相關(guān)產(chǎn)品有：QGY 7701細(xì)胞、LNCaP-Clone-FGC細(xì)胞、SKRC20細(xì)胞

Capan-2 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，２-３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：多邊形;相關(guān)產(chǎn)品有：H-1341細(xì)胞、Hopkins-92細(xì)胞、WEHI-3B細(xì)胞

HBSMC Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Hs 832(C).T細(xì)胞、HC11 Mammary Epithelium細(xì)胞、EL4細(xì)胞

SLMT-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：L5178Y TK+/- (clone 3.7.2C)細(xì)胞、SW954細(xì)胞、Walker-256-TC細(xì)胞

HBL-100 Cells;背景說明：該細(xì)胞由E.V.Gaffney及其同事從一位沒有乳癌家族史的供者乳汁中建立，培養(yǎng)出來的細(xì)胞染色體組型在第７代時(shí)就不正常；電鏡照片顯示有微絲、張力原纖維和橋粒；Southern轉(zhuǎn)移表明有整合型SV４０病毒基因，當(dāng)作正常細(xì)胞。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：Instituto Biologico-Rim Suino-2細(xì)胞、BT-20細(xì)胞、H-2170細(xì)胞

Hs819.T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２—１：３傳代；每周換液２-３次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：成纖維;相關(guān)產(chǎn)品有：CBRH7919細(xì)胞、SF 126細(xì)胞、786.O細(xì)胞

BayGenomics ES cell line RRO624 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line YHC102 Cells(提供STR鑒定圖譜)

HCD-57 SHP2-E76K Cells(提供STR鑒定圖譜)

PCRP-CCDC101-1D10 Cells(提供STR鑒定圖譜)

BP8 Cells(提供STR鑒定圖譜)

HPS0320 Cells(提供STR鑒定圖譜)

" "PubMed=327080; DOI=10.1093/jnci/59.1.221

Fogh J., Fogh J.M., Orfeo T.

One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.

J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209

Fogh J., Wright W.C., Loveless J.D.

Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=864752; DOI=10.1093/jnci/58.6.1743

Marshall C.J., Franks L.M., Carbonell A.W.

Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas.

J. Natl. Cancer Inst. 58:1743-1751(1977)

PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x

Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.

Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.

Tissue Antigens 11:279-286(1978)

PubMed=626984

Erickson L.C., Osieka R., Kohn K.W.

Differential repair of 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1- nitrosourea-induced DNA damage in two human colon tumor cell lines.

Cancer Res. 38:802-808(1978)

PubMed=468301; PMCID=PMC1457289

Trejdosiewicz L.K., Trejdosiewicz A.J., Ling N.R., Dykes P.W.

Growth enhancing property of human monocytes from normal donors and cancer patients.

Immunology 37:247-252(1979)

PubMed=6256643; DOI=10.1038/288724a0

Day R.S. 3rd, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Lubiniecki A.S., Girardi A.J., Galloway S.M., Bynum G.D.

Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains.

Nature 288:724-727(1980)

PubMed=6445228

Kimball P.M., Brattain M.G.

Isolation of a cellular subpopulation from a human colonic carcinoma cell line.

Cancer Res. 40:1574-1579(1980)

PubMed=22282976; DOI=10.1093/carcin/1.1.21

Day R.S. 3rd, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Mattern M.R.

Human tumor cell strains defective in the repair of alkylation damage.

Carcinogenesis 1:21-32(1980)

PubMed=7017212; DOI=10.1093/jnci/66.6.1003

Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.

HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.

J. Natl. Cancer Inst. 66:1003-1012(1981)

PubMed=7459858

Rousset M., Zweibaum A., Fogh J.

Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.

Cancer Res. 41:1165-1170(1981)

PubMed=6220172

Dracopoli N.C., Fogh J.

Polymorphic enzyme analysis of cultured human tumor cell lines.

J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=6825208; DOI=10.1093/carcin/4.2.199

Yarosh D.B., Foote R.S., Mitra S., Day R.S. 3rd

Repair of O6-methylguanine in DNA by demethylation is lacking in Mer- human tumor cell strains.

Carcinogenesis 4:199-205(1983)

PubMed=6500159; DOI=10.1159/000163283

Gershwin M.E., Lentz D., Owens R.B.

Relationship between karyotype of tissue culture lines and tumorigenicity in nude mice.

Exp. Cell Biol. 52:361-370(1984)

PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720

Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.

Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.

Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

PubMed=3472642; DOI=10.1016/0165-4608(87)90267-6

Chen T.-R., Drabkowski D.J., Hay R.J., Macy M.L., Peterson W.D. Jr.

WiDr is a derivative of another colon adenocarcinoma cell line, HT-29.

Cancer Genet. Cytogenet. 27:125-134(1987)

PubMed=3335022

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Cancer Res. 48:589-601(1988)

PubMed=3349466

Chantret I., Barbat A., Dussaulx E., Brattain M.G., Zweibaum A.

Epithelial polarity, villin expression, and enterocytic differentiation of cultured human colon carcinoma cells: a survey of twenty cell lines.

Cancer Res. 48:1936-1942(1988)

PubMed=2288877

Hafez M.M., Infante D., Winawer S.J., Friedman E.

Transforming growth factor beta 1 acts as an autocrine-negative growth regulator in colon enterocytic differentiation but not in goblet cell maturation.

Cell Growth Differ. 1:617-626(1990)

PubMed=1778766; DOI=10.1111/j.1349-7006.1991.tb01816.x; PMCID=PMC5918361

Takeshima E., Hamaguchi M., Watanabe T., Akiyama S., Kataoka M., Ohnishi Y., Xiao H.-Y., Nagai Y., Takagi H.

Aberrant elevation of tyrosine-specific phosphorylation in human gastric cancer cells.

Jpn. J. Cancer Res. 82:1428-1435(1991)

PubMed=1937958; DOI=10.1002/ijc.2910490516

Lesuffleur T., Kornowski A., Luccioni C., Muleris M., Barbat A., Beaumatin J., Dussaulx E., Dutrillaux B., Zweibaum A.

Adaptation to 5-fluorouracil of the heterogeneous human colon tumor cell line HT-29 results in the selection of cells committed to differentiation.

Int. J. Cancer 49:721-730(1991)

PubMed=2041050; DOI=10.1093/jnci/83.11.757

Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D., Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

J. Natl. Cancer Inst. 83:757-766(1991)

PubMed=1389533; DOI=10.1016/0959-8049(92)90031-V

Lahm H., Petral-Malec D., Yilmaz-Ceyhan A., Fischer J.R., Lorenzoni M., Givel J.-C., Odartchenko N.

Growth stimulation of a human colorectal carcinoma cell line by interleukin-1 and -6 and antagonistic effects of transforming growth factor beta 1.

Eur. J. Cancer 28A:1894-1899(1992)

PubMed=1730571; DOI=10.1007/BF02631079

Goodwin T.J., Jessup J.M., Wolf D.A.

Morphologic differentiation of colon carcinoma cell lines HT-29 and HT-29KM in rotating-wall vessels.

In Vitro Cell. Dev. Biol. Anim. 28:47-60(1992)

PubMed=8464898; DOI=10.1073/pnas.90.7.2842; PMCID=PMC46192

Browning M.J., Krausa P., Rowan A.J., Bicknell D.C., Bodmer J.G., Bodmer W.F.

Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines.

Proc. Natl. Acad. Sci. U.S.A. 90:2842-2845(1993)

PubMed=7972006; DOI=10.1073/pnas.91.23.11045; PMCID=PMC45163

Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P., Bennett W.P., Forrester K., Gerwin B.I., Serrano M., Beach D.H., Harris C.C.

Mutations and altered expression of p16INK4 in human cancer.

Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994)

PubMed=7651727

Kastrinakis W.V., Ramchurren N., Rieger K.M., Hess D.T., Loda M., Steele G., Summerhayes I.C.

Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression.

Oncogene 11:647-652(1995)

PubMed=8895552; DOI=10.1002/(SICI)1097-0215(19960927)68:1<126::AID-IJC22>3.0.CO;2-8

Suardet L., Li C., Little J.B.

Radio-induced modulation of transforming growth factor beta1 sensitivity in a p53 wild-type human colorectal-cancer cell line.

Int. J. Cancer 68:126-131(1996)

PubMed=9000147

Cottu P.-H., Muzeau F., Estreicher A., Flejou J.-F., Iggo R.D., Thomas G., Hamelin R.

Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines.

Oncogene 13:2727-2730(1996)

PubMed=9000572

Hoang J.-M., Cottu P.-H., Thuille B., Salmon R.J., Thomas G., Hamelin R.

BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines.

Cancer Res. 57:300-303(1997)

PubMed=9294210; DOI=10.1073/pnas.94.19.10330; PMCID=PMC23362

Ilyas M., Tomlinson I.P.M., Rowan A.J., Pignatelli M., Bodmer W.F.

Beta-catenin mutations in cell lines established from human colorectal cancers.

Proc. Natl. Acad. Sci. U.S.A. 94:10330-10334(1997)

PubMed=10612807; DOI=10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; PMCID=PMC4721570

Ghadimi B.M., Sackett D.L., Difilippantonio M.J., Schrock E., Neumann T., Jauho A., Auer G., Ried T.

Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations.

Genes Chromosomes Cancer 27:183-190(2000)

PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)

PubMed=10737795; DOI=10.1073/pnas.97.7.3352; PMCID=PMC16243

Rowan A.J., Lamlum H., Ilyas M., Wheeler J.M.D., Straub J., Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.

APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'.

Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000)

PubMed=11226274; DOI=10.1073/pnas.041603298; PMCID=PMC30173

Abdel-Rahman W.M., Katsura K., Rens W., Gorman P.A., Sheer D., Bicknell D.C., Bodmer W.F., Arends M.J., Wyllie A.H., Edwards P.A.W.

Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement.

Proc. Natl. Acad. Sci. U.S.A. 98:2538-2543(2001)

PubMed=11414198; DOI=10.1007/s004320000207

Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.-J.

Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.

J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459

Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Short tandem repeat profiling provides an international reference standard for human cell lines.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=11526487; DOI=10.1038/sj.onc.1204611

Gayet J., Zhou X.-P., Duval A., Rolland S., Hoang J.-M., Cottu P.-H., Hamelin R.

Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines.

Oncogene 20:5025-5032(2001)

PubMed=11668190; DOI=10.1177/002215540104901105

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

Immunocytochemical analysis of cell lines derived from solid tumors.

J. Histochem. Cytochem. 49:1369-1378(2001)

PubMed=11687795; DOI=10.1038/ng754

Snijders A.M., Nowak N.J., Segraves R., Blackwood S., Brown N., Conroy J., Hamilton G., Hindle A.K., Huey B., Kimura K., Law S., Myambo K., Palmer J., Ylstra B., Yue J.P., Gray J.W., Jain A.N., Pinkel D., Albertson D.G.

Assembly of microarrays for genome-wide measurement of DNA copy number.

Nat. Genet. 29:263-264(2001)

PubMed=11921276; DOI=10.1002/gcc.10003

Kawai K., Viars C., Arden K.C., Tarin D., Urquidi V., Goodison S.

Comprehensive karyotyping of the HT-29 colon adenocarcinoma cell line.

Genes Chromosomes Cancer 34:1-8(2002)

PubMed=12068308; DOI=10.1038/nature00766

Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Mutations of the BRAF gene in human cancer.

Nature 417:949-954(2002)

PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742

Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. 3rd, Stroncek D., Marincola F.M.

HLA class I and II genotype of the NCI-60 cell lines.

J. Transl. Med. 3:11.1-11.8(2005)

PubMed=15900046; DOI=10.1093/jnci/dji133

Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T.

p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target.

J. Natl. Cancer Inst. 97:765-777(2005)

PubMed=16083285; DOI=10.1021/pr050048h

Kim J.-E., Tannenbaum S.R., White F.M.

Global phosphoproteome of HT-29 human colon adenocarcinoma cells.

J. Proteome Res. 4:1339-1346(2005)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832

Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Miroo T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=18258742; DOI=10.1073/pnas.0712176105; PMCID=PMC2268141

Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.

Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.

Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356

Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.

DNA fingerprinting of the NCI-60 cell line panel.

Mol. Cancer Ther. 8:713-724(2009)

PubMed=19927377; DOI=10.1002/gcc.20730; PMCID=PMC2818350

Knutsen T., Padilla-Nash H.M., Wangsa D., Barenboim-Stapleton L., Camps J., McNeil N.E., Difilippantonio M.J., Ried T.

Definitive molecular cytogenetic characterization of 15 colorectal cancer cell lines.

Genes Chromosomes Cancer 49:204-223(2010)

PubMed=19941903; DOI=10.1016/j.jviromet.2009.11.022

Karger A., Bettin B., Lenk M., Mettenleiter T.C.

Rapid characterisation of cell cultures by matrix-assisted laser desorption/ionisation mass spectrometric typing.

J. Virol. Methods 164:116-121(2010)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192; PMCID=PMC2943514

Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S., Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.M., Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M., Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Cancer Res. 70:5901-5911(2010)

PubMed=20606684; DOI=10.1038/sj.bjc.6605780; PMCID=PMC2920028

Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.

5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.

Br. J. Cancer 103:340-346(2010)

PubMed=20831567; DOI=10.1111/j.1582-4934.2010.01170.x; PMCID=PMC3918049

Ma Y.-L., Zhang P., Wang F., Moyer M.P., Yang J.-J., Liu Z.-H., Peng J.-Y., Chen H.-Q., Zhou Y.-K., Liu W.-J., Qin H.-L.

Human embryonic stem cells and metastatic colorectal cancer cells shared the common endogenous human microRNA-26b.

J. Cell. Mol. Med. 15:1941-1954(2011)

PubMed=22068913; DOI=10.1073/pnas.1111840108; PMCID=PMC3219108

Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=21912889; DOI=10.1007/s10637-011-9744-z

Sutherland H.S., Hwang I.Y., Marshall E.S., Lindsay B.S., Denny W.A., Gilchrist C., Joseph W.R., Greenhalgh D., Richardson E., Kestell P., Ding A., Baguley B.C.

Therapeutic reactivation of mutant p53 protein by quinazoline derivatives.

Invest. New Drugs 30:2035-2045(2012)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017

Kong D.-X., Yamori T.

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.

Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22347499; DOI=10.1371/journal.pone.0031628; PMCID=PMC3276511

Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.

Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.

PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096; PMCID=PMC3285665

Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.

Identification of cancer cell-line origins using fluorescence image-based phenomic screening.

PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=22628656; DOI=10.1126/science.1218595; PMCID=PMC3526189

Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.

Science 336:1040-1044(2012)

PubMed=23272949; DOI=10.1186/1755-8794-5-66; PMCID=PMC3543849

Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A., Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A., Orphanides G., French T., Wessels L.F.A.

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines.

BMC Med. Genomics 5:66.1-66.15(2012)

PubMed=22940288; DOI=10.1016/j.jsbmb.2012.08.003; PMCID=PMC3695570

Hobaus J., Fetahu I.S., Khorchide M., Manhardt T., Kallay E.

Epigenetic regulation of the 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1) in colon cancer cells.

J. Steroid Biochem. Mol. Biol. 136:296-299(2013)

PubMed=23546019; DOI=10.3892/ijo.2013.1868

Petitprez A., Poindessous V., Ouaret D., Regairaz M., Bastian G., Guerin E., Escargueil A.E., Larsen A.K.

Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status.

Int. J. Oncol. 42:1644-1653(2013)

PubMed=23631600; DOI=10.1021/pr400260h

Loftus N.J., Lai L., Wilkinson R.W., Odedra R., Wilson I.D., Barnes A.J.

Global metabolite profiling of human colorectal cancer xenografts in mice using HPLC-MS/MS.

J. Proteome Res. 12:2980-2986(2013)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342; PMCID=PMC4893961

Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Cancer Res. 73:4372-4382(2013)

PubMed=23932154; DOI=10.1016/j.radonc.2013.06.032

Salendo J., Spitzner M., Kramer F., Zhang X., Jo P., Wolff H.A., Kitz J., Kaulfuss S., Beissbarth T., belstein M., Ghadimi M., Grade M., Gaedcke J.

Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g.

Radiother. Oncol. 108:451-457(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018

Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.

Global proteome analysis of the NCI-60 cell line panel.

Cell Rep. 4:609-620(2013)

PubMed=24042735; DOI=10.1038/oncsis.2013.35; PMCID=PMC3816225

Ahmed D., Eide P.W., Eilertsen I.A., Danielsen S.A., Eknaes M., Hektoen M., Lind G.E., Lothe R.A.

Epigenetic and genetic features of 24 colon cancer cell lines.

Oncogenesis 2:e71.1-e71.8(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20; PMCID=PMC4178206

Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Cancer Metab. 1:20.1-20.13(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047; PMCID=PMC3966786

Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

PLoS ONE 9:E92047-E92047(2014)

PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013

Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S., Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S., O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F., Mariadason J.M., Sieber O.M.

Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.

Cancer Res. 74:3238-3247(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35; PMCID=PMC4432652

Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25841592; DOI=10.1016/j.jprot.2015.03.019

Piersma S.R., Knol J.C., de Reus I., Labots M., Sampadi B.K., Pham T.V., Ishihama Y., Verheul H.M.W., Jimenez C.R.

Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines.

J. Proteomics 127:247-258(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=25926053; DOI=10.1038/ncomms8002

Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G., Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S., Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M., Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

Nat. Commun. 6:7002.1-7002.10(2015)

PubMed=25944804; DOI=10.1158/1078-0432.CCR-14-2457

Bazzocco S., Dopeso H., Carton-Garcia F., Macaya I., Andretta E., Chionh F., Rodrigues P., Garrido M., Alazzouzi H., Nieto R., Sanchez A., Schwartz S. Jr., Bilic J., Mariadason J.M., Arango D.

Highly expressed genes in rapidly proliferating tumor cells as new targets for colorectal cancer treatment.

Clin. Cancer Res. 21:3695-3704(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=29787047; DOI=10.1007/978-3-319-16104-4_11

Martinez-Maqueda D., Miralles B., Recio I.

HT29 cell line.

(In book chapter) The impact of food bioactives on health. In vitro and ex vivo models; Verhoeckx K., Cotter P., Lopez-Exposito I., Kleiveland C., Lea T., Mackie A., Requena T., Swiatecka D., Wichers H. (eds.); pp.113-124; Springer; Cham; Switzerland (2015)

PubMed=26537799; DOI=10.1074/mcp.M115.051235; PMCID=PMC4762531

Holst S., Deuss A.J.M., van Pelt G.W., van Vliet S.J., Garcia-Vallejo J.J., Koeleman C.A.M., Deelder A.M., Mesker W.E., Tollenaar R.A.E.M., Rombouts Y., Wuhrer M.

N-glycosylation profiling of colorectal cancer cell lines reveals association of fucosylation with differentiation and caudal type homebox 1 (CDX1)/villin mRNA expression.

Mol. Cell. Proteomics 15:124-140(2016)

PubMed=27377824; DOI=10.1038/sdata.2016.52; PMCID=PMC4932877

Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.

Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.

Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4; PMCID=PMC5087121

Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.

A map of mobile DNA insertions in the NCI-60 human cancer cell panel.

Mob. DNA 7:20.1-20.11(2016)

PubMed=28179481; DOI=10.1158/1535-7163.MCT-16-0578

Tanaka N., Mashima T., Mizutani A., Sato A., Aoyama A., Gong B., Yoshida H., Muramatsu Y., Nakata K., Matsuura M., Katayama R., Nagayama S., Fujita N., Sugimoto Y., Seimiya H.

APC mutations as a potential biomarker for sensitivity to tankyrase inhibitors in colorectal cancer.

Mol. Cancer Ther. 16:752-762(2017)

PubMed=28192450; DOI=10.1371/journal.pone.0171435; PMCID=PMC5305277

Fasterius E., Raso C., Kennedy S.A., Rauch N., Lundin P., Kolch W., Uhlen M., Al-Khalili Szigyarto C.

A novel RNA sequencing data analysis method for cell line authentication.

PLoS ONE 12:E0171435-E0171435(2017)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=28683746; DOI=10.1186/s12943-017-0691-y; PMCID=PMC5498998

Berg K.C.G., Eide P.W., Eilertsen I.A., Johannessen B., Bruun J., Danielsen S.A., Bjornslett M., Meza-Zepeda L.A., Eknaes M., Lind G.E., Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.

Multi-omics of 34 colorectal cancer cell lines -- a resource for biomedical studies.

Mol. Cancer 16:116.1-116.16(2017)

PubMed=28854368; DOI=10.1016/j.celrep.2017.08.010; PMCID=PMC5583477

Roumeliotis T.I., Williams S.P., Goncalves E., Alsinet C., Del Castillo Velasco-Herrera M., Aben N., Ghavidel F.Z., Michaut M., Schubert M., Price S., Wright J.C., Yu L., Yang M., Dienstmann R., Guinney J.H., Beltrao P., Brazma A., Pardo M., Stegle O., Adams D.J., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.

Genomic determinants of protein abundance variation in colorectal cancer cells.

Cell Rep. 20:2201-2214(2017)

PubMed=29101300; DOI=10.15252/msb.20177701; PMCID=PMC5731344

Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R.-S., Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S., Johnstone E., Domingo E., Kerr D.J., Jesinghaus M., Slotta-Huspenina J., Weichert W., Knapp S., Feller S.M., Kuster B.

Pharmacoproteomic characterisation of human colon and rectal cancer.

Mol. Syst. Biol. 13:951-951(2017)

PubMed=29207035; DOI=10.3892/ijo.2017.4206

Olejniczak A., Szarynska M., Kmiec Z.

In vitro characterization of spheres derived from colorectal cancer cell lines.

Int. J. Oncol. 52:599-612(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9

Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Nature 568:511-516(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254

Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.

Quantitative proteomics of the Cancer Cell Line Encyclopedia.

Cell 180:387-402.e16(2020)

PubMed=32172478; DOI=10.1007/s12253-020-00805-3

Xu Y.-T., Zhang L., Wang Q.-L., Zheng M.-J.

Comparison of different colorectal cancer with liver metastases models using six colorectal cancer cell lines.

Pathol. Oncol. R"